OSLO, June 14, 2024: The Annual General Meeting of EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), will be held as a virtual meeting at 10:30 CEST on 28th June 2024.
The notice of the Annual General Meeting with Attendance/Proxy forms, including the Board of Directors' proposed resolutions for the items listed on the agenda. The documents are also available at www.exact-tx.com. The deadline for receiving proxies or attendance registration is 26th June 2024 at 12:00 CEST.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
John M. Edminson, CFO
EXACT Therapeutics
Email: john.edminson@exact-tx.com
About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com